Journal of Clinical Oncology
Articles in this Issue
Zolbetuximab in CLDN18.2-positive biliary tract cancer after prior systemic therapy: A prospective observational pilot cohort study of early outcomes, safety, and patient-reported quality of life.
e16174 Background: CLDN18.2 is a validated therapeutic target in advanced gastric and gastroesophageal junction cancer; ho...
Impact of high-risk genomic alterations on survival outcomes in patients with stage III non–small cell lung cancer treated with chemoradiation and consolidation durvalumab.
e20042 Background: Concurrent chemoradiation (CCRT) followed by programmed death ligand-1 (PD-L1) checkpoint inhibition wi...
Understanding the impact of an established oncology program for adolescents and young adults: The role of school and work transitions counseling.
e24111 Background: Adolescent and young adult (AYA) oncology programs provide tailored, multidisciplinary care addressing...
Can we omit surgical axillary staging in early-stage invasive lobular carcinoma?: Results from a large multicenter retrospective cohort study.
588 Background: The SOUND, INSEMA and BOOG 2013-08 randomized trials demonstrated that, in selected patients with clinical...
Phase 1, FIH study of cabotamig, a TCE CDH17 X CD3, in CDH17-expressing GI malignancies.
3603 Background: Cadherin-17 (CDH17) is a specific cancer target; aberrant expression is up to >95% in GI tumors (stoma...
Safety-aligned evaluation of large language models for oncology clinical decision support across disease subtypes.
e13701 Background: Large language models (LLMs) are increasingly evaluated for oncology clinical decision support; however...
A phase 3, international, multicenter, randomized, controlled trial of selective index lymph node resection versus therapeutic lymph node dissection after neoadjuvant immunotherapy for stage IIIB-D melanoma (MSLT-3/S2601/EORTC2519).
TPS9609 Background: Neoadjuvant immunotherapy (NAT) with immune checkpoint inhibitors (ICI) is a standard therapy for rese...
Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis.
2652 Background: Circulating Tumor Cells (CTCs) are prognostic for poor outcomes in metastatic Breast Cancer (mBC), howeve...
Multimodal AI prediction of head and neck cancer treatment outcomes with whole slide imaging.
e18000 Background: Current risk stratification and adjuvant treatment decisions for head and neck cancer following...
Inpatient outcomes in acute myeloid leukemia: A contemporary national study.
e18615 Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with high morbidity, fr...
Characteristics and clinical outcomes of newly diagnosed acute myeloid leukemia with MAPK pathway mutations: A referral-center retrospective analysis.
e18506 Background: Somatic mutations in the MAPK signaling pathway are frequently identified and implicated in the disease...
Burden of liver metastases among pancreatic cancer patients in the United States.
e16160 Background: Liver metastasis is a common and severe complication in pancreatic cancer, contributing significantly t...
Organ-specific metastatic progression in non-small cell lung cancer treated with pembrolizumab versus atezolizumab: A TrinetX network analysis.
11182 Background: Immune checkpoint inhibitors (ICIs) targeting the PD-1 (Pembrolizumab) and PD-L1 (Atezolizumab) have rev...
A randomized controlled trial of a multilingual digital genetic cancer risk assessment tool in a diverse patient population.
10619 Background: Most individuals with hereditary cancer risk remain unidentified, particularly racial, ethnic, and lingu...
Burnout among caregivers of hospitalized medical oncology patients: A cross-sectional survey study.
12086 Background: Caregivers of patients hospitalized in medical oncology wards play a crucial role in daily care and clin...
Analysis of early access to cancer medicines in the United Kingdom following incorporation of the FDA-coordinated pathway, Project Orbis.
e23043 Background: After its withdrawal from the European Union, the United Kingdom (UK) transitioned to international reg...
Evaluation of the NorthStar ctDNA assay for monitoring gastrointestinal malignancies: A retrospective analysis.
e15058 Background: Liquid biopsies offer a non-invasive alternative to traditional tissue biopsy for guiding therapy and r...
An open-label phase 1 study of DCC-2812 monotherapy in patients with advanced genitourinary cancers.
TPS4639 Background: The integrated stress response (ISR) is a major adaptive cellular response pathway that cancer cells d...
Associations of autoimmune diseases with appendiceal cancer in a population-based study.
e16495 Background: Appendiceal cancer has a fast rising incidence, especially in younger adults. Causal factors of appendi...
FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
6020 Background: Paclitaxel is commonly used to treat HNSCC but is associated with infusion-related reactions and peripher...
Paclitaxel/cisplatin (TP) vs cisplatin/5-fluorouracil (PF) neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma (ESCC): A randomized trial.
4084 Background: Neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy is standard treatment for patients with re...
Randomized phase II study of amivantamab + lazertinib versus afatinib in patients with uncommon/compound <i>EGFR</i> -mutated non-small cell lung cancer (WJOG17323L: AGEHA study).
TPS8676 Background: While EGFR tyrosine kinase inhibitors (TKIs) such as afatinib are standard treatments for patients wit...
Predictors of biomarker-directed therapy utilization in metastatic colorectal cancer: A real-world analysis.
e15572 Background: The treatment landscape of metastatic colorectal cancer (mCRC) has evolved with identification of actio...
TRUST: An MRI-based AI framework for non-invasive prediction of treatment response and prognosis in breast cancer.
e12556 Background: The tumor microenvironment (TME) plays a pivotal role in therapeutic response and prognosis in breast c...
Combination of vemurafenib with cobimetinib in <i>BRAF</i> V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with nivolumab and ipilimumab (COWBOY): A randomized, open-label phase 2 clinical trial.
9513 Background: Elevated levels of serum lactate dehydrogenase (LDH) in patients (pts) with metastatic melanoma are assoc...